N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works

He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run faster and more efficient trials, and offer more participants a chance to be in experimental arms.